

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
09 September 2022 (09.09.2022)



(10) International Publication Number  
**WO 2022/184824 A2**

(51) International Patent Classification:  
Not classified

(21) International Application Number:  
PCT/EP2022/055394

(22) International Filing Date:  
03 March 2022 (03.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
21160732.0 04 March 2021 (04.03.2021) EP

(71) Applicant: **DEUTSCHES KREBS-  
FORSCHUNGSZENTRUM STIFTUNG DES ÖF-  
FENTLICHEN RECHTS** [DE/DE]; IM NEUEN-  
HEIMER FELD 280, 69120 HEIDELBERG (DE).

(72) Inventors: **HALAMA, Niels**; Deutsches Krebs-  
forschungszentrum, Stiftung des öffentlichen Rechts, In-  
novaion Management, T010, Im Neuenheimer Feld 280,  
69120 Heidelberg (DE). **JÄGER, Dirk**; Deutsches Kreb-  
sforschungszentrum, Stiftung des öffentlichen Rechts, In-  
novaion Management, T010, Im Neuenheimer Feld 280,  
69120 Heidelberg (DE). **SCHMIDT, Patrick**; Deutsches  
Krebsforschungszentrum, Stiftung des öffentlichen Rechts,  
Innovaion Management, T010, Im Neuenheimer Feld 280,  
69120 Heidelberg (DE).

(74) Agent: **SCHÜSSLER, Andrea**; TRUDERINGER  
STRASSE 246, 81825 MÜNCHEN (DE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

**Published:**

- without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))
- in black and white; the international application as filed  
contained color or greyscale and is available for download  
from PATENTSCOPE

(54) Title: CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1

(57) Abstract: The present invention relates to compositions, methods, uses and kits for combination therapies involving immunother-  
apies, such as adaptive cell therapy, e.g., T cell therapy, and an oncolytic virus (particularly parvovirus H-1), for treating subjects  
with cancer. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). In some  
embodiments, the cancer is a solid tumor or a hematological malignancy.

